A new report analyzes the pain management drug development market in the face of expiring patents and increased prescription drug abuse, according to a Reportlinker.com news release.
Drug development has focused on reformulating existing drugs and creating alternative methods of drug delivery to improve safety and efficacy. Currently, there are 75 agents in clinical development. Of the 26 agents indicated for neuropathic pain, six specifically target postherpetic neuralgia. Other indications include diabetic peripheral neuropathy, central neuropathic pain due to spinal cord injury or multiple sclerosis and lumbosacral radiculopathy. Nociceptive pain indications include osteoarthritis pain and chronic low back pain.
Related Articles on Pain Management:
Targeted Radiation Alternative Treatment to Surgery for Trigeminal Neuralgia
Pharmacists Stop Stocking Opioids Due to Robberies
12 Statistics on Pain Management Case Revenue by Region
Drug development has focused on reformulating existing drugs and creating alternative methods of drug delivery to improve safety and efficacy. Currently, there are 75 agents in clinical development. Of the 26 agents indicated for neuropathic pain, six specifically target postherpetic neuralgia. Other indications include diabetic peripheral neuropathy, central neuropathic pain due to spinal cord injury or multiple sclerosis and lumbosacral radiculopathy. Nociceptive pain indications include osteoarthritis pain and chronic low back pain.
Related Articles on Pain Management:
Targeted Radiation Alternative Treatment to Surgery for Trigeminal Neuralgia
Pharmacists Stop Stocking Opioids Due to Robberies
12 Statistics on Pain Management Case Revenue by Region